Immunomodulators as adjunctive therapy for HIV-1 infectionPETT, Sarah L; EMERY, Sean.Journal of clinical virology. 2001, Vol 22, Num 3, pp 289-295, issn 1386-6532Conference Paper

Skeletal Muscle Toxicity Associated With Raltegravir-Based Combination Antiretroviral Therapy in HIV-Infected AdultsLEE, Frederick J; AMIN, Janaki; BLOCH, Mark et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 62, Num 5, pp 525-533, issn 1525-4135, 9 p.Article

Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapyHSU, Denise C; KERR, Stephen J; COOPER, David A et al.The Journal of infection. 2014, Vol 68, Num 4, pp 344-354, issn 0163-4453, 11 p.Article

A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated AdultsCAREY, Dianne; PETT, Sarah L; BLOCH, Mark et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 60, Num 2, pp 143-149, issn 1525-4135, 7 p.Article

Enfuvirtide injection site reactions: A clinical and histopathological appraisalWALLACE, Brian J; TAN, King-Bing; PETT, Sarah L et al.Australasian journal of dermatology. 2011, Vol 52, Num 1, pp 19-26, issn 0004-8380, 8 p.Article

A Novel Chemokine-Receptor-5 (CCR5) Blocker, SCH532706, Has Differential Effects on CCR5⁺CD4⁺ and CCR5⁺CD8⁺ T Cell Numbers in Chronic HIV InfectionPETT, Sarah L; ZAUNDERS, John; BAILEY, Michelle et al.AIDS research and human retroviruses. 2010, Vol 26, Num 6, pp 653-661, issn 0889-2229, 9 p.Article